Susan Shiff
Direttore/Membro del Consiglio presso CARA THERAPEUTICS, INC.
Patrimonio netto: 131 153 $ in data 31/05/2024
Profilo
Susan Patricia Shiff is an Independent Director at CARA Therapeutics, Inc. She is also a Director at Merck Global Health Innovation Fund LLC, Synthace Ltd., and a Trustee at New Jersey Symphony Orchestra.
Previously, she served as a Senior Vice President at Merck & Co., Inc. from 2014 to 2021.
She also held positions as a Vice President at Pfizer Inc. and Teva Pharmaceutics.
In addition, she was the President of Ontada LLC from 2021 to 2023.
Dr. Shiff holds a doctorate degree from the University of California, Los Angeles and an MBA from Cornell University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CARA THERAPEUTICS INC
0.37% | 04/06/2024 | 202 085 ( 0.37% ) | 131 153 $ | 31/05/2024 |
Posizioni attive di Susan Shiff
| Società | Posizione | Inizio |
|---|---|---|
| CARA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 26/06/2020 |
Synthace Ltd.
 Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Direttore/Membro del Consiglio | 05/06/2018 |
Merck Global Health Innovation Fund LLC
 Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe primarily in North America and Europe. The fund focuses on companies operating in the fields of digital health, drug discovery & clinical development, manufacturing, supply chain & it services. It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Direttore/Membro del Consiglio | - |
| New Jersey Symphony Orchestra | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Susan Shiff
| Società | Posizione | Fine |
|---|---|---|
| Ontada | Presidente | 01/07/2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/03/2021 |
| Teva Pharmaceutics | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formazione di Susan Shiff
| University of California, Los Angeles | Doctorate Degree |
| Cornell University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| CARA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
| New Jersey Symphony Orchestra | |
| Teva Pharmaceutics | |
Merck Global Health Innovation Fund LLC
Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe primarily in North America and Europe. The fund focuses on companies operating in the fields of digital health, drug discovery & clinical development, manufacturing, supply chain & it services. It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Finance |
Synthace Ltd.
Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Technology Services |
| Ontada |
- Borsa valori
- Insiders
- Susan Shiff
